CLDN18 and neoplasm: Which clinical or molecular subgroups benefit most from HIPEC is also unknown, partly because clinicians often lack data on key biomarkers (e.g., PD-L1 expression, tumor mutational burden, microsatellite stability, CLDN18.2 status).